Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Rating of “Buy” from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given a consensus recommendation of “Buy” by the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $24.44.

Several research firms have commented on TEVA. Bank of America boosted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a “buy” rating and a $25.00 target price on the stock. Finally, The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a “buy” rating and a $24.00 target price on the stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president now owns 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. Rhumbline Advisers raised its holdings in shares of Teva Pharmaceutical Industries by 0.8% during the 1st quarter. Rhumbline Advisers now owns 281,062 shares of the company’s stock worth $4,320,000 after acquiring an additional 2,128 shares during the period. Strs Ohio purchased a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $2,354,000. Geneos Wealth Management Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 49.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 34,547 shares of the company’s stock valued at $531,000 after buying an additional 11,425 shares during the period. Intech Investment Management LLC lifted its stake in Teva Pharmaceutical Industries by 43.6% in the first quarter. Intech Investment Management LLC now owns 349,340 shares of the company’s stock worth $5,369,000 after acquiring an additional 106,108 shares during the last quarter. Finally, Focus Partners Wealth grew its stake in shares of Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after purchasing an additional 1,739 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $17.30 on Thursday. The stock’s 50 day moving average price is $15.90 and its 200-day moving average price is $17.40. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock has a market capitalization of $19.84 billion, a PE ratio of -11.93, a price-to-earnings-growth ratio of 1.44 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same period last year, the business posted $0.48 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.